Search

From art to science: How one Sarepta scientist brings arts into the lab
Advocacy community unites to support families
How Sarepta infused its corporate brand with urgency and optimism on behalf of patients
Patiently waiting
Corporate Responsibility
Seeing hope at genetic medicine's frontier: Meet Stefanie Mason, M.D.
Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Announces First Quarter 2023 Financial Results and Recent Corporate Developments
Sarepta Therapeutics to Announce First Quarter 2023 Financial Results